Cronos Group Inc
TSX:CRON
Relative Value
The Relative Value of one
CRON
stock under the Base Case scenario is
0.25
CAD.
Compared to the current market price of 3.6 CAD,
Cronos Group Inc
is
Overvalued by 93%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
CRON Competitors Multiples
Cronos Group Inc Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
|
Cronos Group Inc
TSX:CRON
|
1.4B CAD | 7.6 | 27.9 | -28 | -9.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
992.9B USD | 15.2 | 48.1 | 32.4 | 34.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
575.5B USD | 6.1 | 21.5 | 14.9 | 18.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
282.2B CHF | 4.6 | 30 | 12.7 | 14.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
231.1B CHF | 5.3 | 21.2 | 13.1 | 16.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215.7B GBP | 5.1 | 31.7 | 15.1 | 22.2 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
291.1B USD | 4.5 | 16 | 10 | 11.7 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK | 4.6 | 13.8 | 10.1 | 11.8 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.9B USD | 2.5 | 19.8 | 7.4 | 9.9 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
123.2B USD | 2.6 | 17.5 | 6.8 | 8.8 |